Search Follow us

 

Atossa announced this week that it is transferring the site of its ongoing 30-pt Phase II study on intraductal catheter (IDMC) administered fulvestrant to the Montefiore Medical Center in New York City, from the Columbia University Medical Center where it had been initiated in March 2016. This move follows the relocation of the study’s primary investigator, Dr Sheldon M Feldman, from Columbia to Montefiore. Atossa believes this move will hasten patient recruitment, which it acknowledges had been slower than expected. It now expects to finish enrolment by August 2017, whereas it previously guided completion by March 2017.

Continue reading

This version is programmatically created by Responsive Labs and qualified in its entirety to the original PDF.

Powered by Responsive Labs